BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25423931)

  • 1. [New Developments in CKD-MBD. Strategies for the management of predilalysis CKD-MBD].
    Ando R
    Clin Calcium; 2014 Dec; 24(12):1845-51. PubMed ID: 25423931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New Developments in CKD-MBD. How to "Thinking Global! Acting Local" for treating CKD-MBD].
    Tsukamoto Y
    Clin Calcium; 2014 Dec; 24(12):1757-61. PubMed ID: 25423919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
    Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
    J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New Developments in CKD-MBD. Cell Biology of parathyroid in CKD].
    Kakuta T; Sawada K
    Clin Calcium; 2014 Dec; 24(12):1801-8. PubMed ID: 25423925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteo-renal regulation of systemic phosphate metabolism.
    Razzaque MS
    IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of phosphate binders: a perspective on novel therapeutics.
    Cernaro V; Santoro D; Lucisano S; Nicocia G; Lacquaniti A; Buemi M
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1459-63. PubMed ID: 25243756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic kidney disease and nutrition].
    Yoshida T; Kumagai H
    Clin Calcium; 2016 Mar; 26(3):369-74. PubMed ID: 26923973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New Developments in CKD-MBD. Development and progression of CKD-MBD in predialysis period -when and how?].
    Komaba H
    Clin Calcium; 2014 Dec; 24(12):1771-8. PubMed ID: 25423921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
    Cozzolino M; Bruschetta E; Cusi D; Montanari E; Giovenzana ME; Galassi A
    Expert Opin Pharmacother; 2012 Nov; 13(16):2337-53. PubMed ID: 23033914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a quantitative systems pharmacology model of chronic kidney disease: metabolic bone disorder.
    Gaweda AE; McBride DE; Lederer ED; Brier ME
    Am J Physiol Renal Physiol; 2021 Feb; 320(2):F203-F211. PubMed ID: 33308018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].
    Omata M; Fukagawa M; Kakuta T
    Clin Calcium; 2015 May; 25(5):645-53. PubMed ID: 25926567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorus and other aspects of CKD-MBD in the conservative management of chronic kidney disease.
    Shah A
    Panminerva Med; 2017 Jun; 59(2):124-132. PubMed ID: 28290186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?
    Evenepoel P; Rodriguez M; Ketteler M
    Semin Nephrol; 2014 Mar; 34(2):151-63. PubMed ID: 24780470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New Developments in CKD-MBD. New aspects in phosphate binders].
    Yokoyama K
    Clin Calcium; 2014 Dec; 24(12):1815-23. PubMed ID: 25423927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CKD-MBD: impact on management of kidney disease.
    Ogata H; Koiwa F; Kinugasa E; Akizawa T
    Clin Exp Nephrol; 2007 Dec; 11(4):261-268. PubMed ID: 18085385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.